What this Trial Is About

Researchers are studying the potential fast-acting effects of nitrous oxide (N2O) in treating suicidal thoughts across different diagnoses. This Phase 2 trial focuses on adults aged 18 to 65 who have moderate to severe suicidal ideation. The study also explores biological markers using hair and blood samples and brain activity through EEG to understand how the treatment works and predict outcomes. Participants will receive two inhalation treatments during the study. On the first day, they will be randomly given either 50% nitrous oxide mixed with oxygen or a placebo of 50% oxygen mixed with air for 45 minutes. Seven days later, all participants will receive nitrous oxide in an open-label second inhalation. The first inhalation is double-blind, meaning neither patients nor raters know the assignment, but only patients are blinded during the second inhalation. Throughout the study, participants will be evaluated for changes in suicidal thoughts using the Beck Scale for Suicidal Ideation from the start to two days after treatment. Researchers will collect biological samples and perform EEG tests to examine the treatment's effects and mechanisms. Safety and participant compliance will be closely monitored, with the total duration including the initial treatment and follow-up assessments.

Nitrous Oxide in the Treatment of Acute Suicidal Ideation